Trial Profile
Long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis from Swiss cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
- 21 Nov 2016 New trial record